Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan

Phase III data show statistically significant wrinkle-reducing results for up to six months across two trials for Revance's neuromodulator RT002. With a safety study ongoing, the Botox competitor isn't likely to hit the market until 2020, but it's yet another piece of bad news for Allergan.

Syringes stuck in a dartboard

Revance Therapeutics Inc. is riding high after announcing its RT002 (daxibotulinumtoxinA) provided long-lasting wrinkle-reducing effects for up to six months in two Phase III trials, potentially besting Botox (onabotulinumtoxinA), but Allergan PLC threw doubt on such claims and stood by the longevity and market share of its blockbuster product.

The biotech's stock rose 33.7% to close at $34.75 per share on the data unveiled Dec. 5.

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers